Safety and Efficacy of Abaloparatide-SC in Men With Osteo... | NCT03512262

NCT03512262

ID	Type	Description	Link
ATOM	Other Identifier	Radius Health, Inc.

Status Module

Sponsor/Collaborators Module

Oversight Module

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Abaloparatide	Experimental	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen that delivers 30 doses. Participants received a new injection pen every 30 days.	Drug: Abaloparatide
Placebo	Placebo Comparator	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen that delivers 30 doses. Participants received a new injection pen every 30 days.	Drug: Placebo

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Abaloparatide	Drug	Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.	Abaloparatide

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Percent Change From Baseline in Lumbar Spine BMD at Month 12	Lumbar Spine BMD was assessed by DXA scans evaluated by a central imaging laboratory. Lumbar spine scans included L1 through L4. Positive changes from baseline indicate improvement in bone health.	Baseline, Month 12

Secondary Outcomes

Measure	Description	Time Frame
Percent Change From Baseline in Total Hip BMD at Month 12	Total hip BMD was assessed by DXA scans evaluated by a central imaging laboratory. Positive changes from baseline indicate improvement in bone health.	Baseline, Month 12
Percent Change From Baseline in Femoral Neck BMD at Month 12

Eligibility Module

Eligibility Criteria

Key Inclusion Criteria

Healthy ambulatory male from 40 to 85 years of age (inclusive) with primary osteoporosis or osteoporosis associated with hypogonadism.
The participant has a BMD T-score based on female or male reference range (depending on date of enrollment) as assessed by the central imaging vendor of ≤ -2.5 at the lumbar spine (L1-L4) or hip (femoral neck or total hip) by dual energy X-ray absorptiometry (DXA) or ≤ -1.5 and with radiologic evidence of vertebral fracture or a documented history of low-trauma nonvertebral fracture sustained in the past 5 years. Men older than 65 years may be enrolled if they have a BMD T-score ≤ -2.0 even if they do not meet the fracture criteria.
Normal medical history, physical examination, including vital signs, and body mass index.
Hypogonadal participants whose doses of androgens have been stable for at least twelve months before randomization are eligible and may continue therapy during the study.
Laboratory tests within the normal range including serum calcium (albumin-corrected), parathyroid hormone, serum phosphorus and alkaline phosphatase, and thyroid stimulating hormone values.

Key Exclusion Criteria

Presence of abnormalities of the lumbar spine that would prohibit assessment of spinal BMD, defined as having at least 2 radiologically evaluable vertebrae within L1-L4.
A BMD T-score of ≤-3.5 at the total hip, femoral neck, or lumbar spine based on female or male reference range (depending on date of enrollment).
Unevaluable hip BMD or participants who have undergone bilateral hip replacement.
Fragility fracture within the prior twelve months.
History of severe vertebral fracture or >2 moderate vertebral fractures.
History of bone disorders (for example, Paget's disease) other than osteoporosis.
participant with clinical signs of hypogonadism present at screening who plan to initiate testosterone replacement.
History of prior external beam or implant radiation therapy involving the skeleton other than radioiodine.
History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, gastrointestinal, endocrine, central nervous system, hematologic or metabolic diseases, or immunologic, emotional and/or psychiatric disturbances to a degree that would interfere with the interpretation of study data or compromise the safety of the participant.
History of Cushing's disease, growth hormone deficiency or excess, hyperthyroidism, hypo- or hyperparathyroidism or malabsorptive syndromes within the past year.

Contacts/Locations Module

Facility	Status	City	State	ZIP	Country	Contacts
University of Alabama at Birmingham		Birmingham	Alabama	35294	United States
Marin Endocrine Care & Research, Inc.

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
11241160	Background	Rizzoli R, Bonjour JP, Ferrari SL. Osteoporosis, genetics and hormones. J Mol Endocrinol. 2001 Apr;26(2):79-94. doi: 10.1677/jme.0.0260079.
10564229	Background	Mannstadt M, Juppner H, Gardella TJ. Receptors for PTH and PTHrP: their biological importance and functional properties. Am J Physiol. 1999 Nov;277(5):F665-75. doi: 10.1152/ajprenal.1999.277.5.F665.

IPD Sharing Statement Module

No data available

No data is available for this block.

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
FG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Annotation Section

No data available

No data is available for this block.

Document Section

Large Document Module

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Mar 30, 2021	Nov 14, 2022

Derived Section

Miscellaneous Info Module

Submission Tracking

Condition Browse Module

Intervention Browse Module

Masking Info

ITT Population: All participants randomized into the study.

Arm/Group Information

ID	Title	Description
BG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
BG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.
BG002	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Mean

Standard Deviation

years

Title

Denominators

Categories

Title	Measurements
	BG00068.5± 8.25 BG00167.8± 8.53 BG00268.3± 8.34

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG0000 BG0010 BG002

Race/Ethnicity, Customized

Count of Participants

Participants

Title

Denominators

Categories

Race: White

Title	Measurements
	BG000140 BG00176 BG002

Lumbar Spine Bone Mineral Density (BMD) T-score

The bone mineral density (BMD) T-score is the BMD, assessed by dual energy x-ray absorptiometry (DXA), at the site when compared to that of a healthy man/woman (20 to 29 years old). Normal is a T-score of -1.0 or higher; Osteopenia is defined as between -1.0 and -2.5; Osteoporosis is defined as -2.5 or lower, meaning a bone density that is two and a half standard deviations below the mean of a man/woman (20 to 29 years old). Lower T-scores indicate worse bone condition.

Mean

Standard Deviation

BMD T-Score

Title

Denominators

Categories

Title	Measurements
	BG000-2.11± 1.119 BG001

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Percent Change From Baseline in Lumbar Spine BMD at Month 12

Lumbar Spine BMD was assessed by DXA scans evaluated by a central imaging laboratory. Lumbar spine scans included L1 through L4. Positive changes from baseline indicate improvement in bone health.

Intent-to-Treat (ITT) Population: All participants randomized into the study. Here, overall number of participants analyzed = participants evaluable for this outcome measure.

Posted

Least Squares Mean

Standard Error

percent change

Baseline, Month 12

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000119 OG00166

Title

Denominators

Categories

Title	Measurements
	OG0008.4820± 0.5353 OG0011.1654± 0.7235

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001		ANCOVA	Missing values were imputed using a multiple imputation method.	<0.0001	Significance level of 0.01.	Least Squares (LSM) Means Difference	7.3165			2-Sided	99	5.0668	9.5663					Superiority

Secondary

Percent Change From Baseline in Total Hip BMD at Month 12

Total hip BMD was assessed by DXA scans evaluated by a central imaging laboratory. Positive changes from baseline indicate improvement in bone health.

ITT Population: All participants randomized into the study. Here, overall number of participants analyzed = participants evaluable for this outcome measure.

Posted

Least Squares Mean

Standard Error

percent change

Baseline, Month 12

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000

Secondary

Percent Change From Baseline in Femoral Neck BMD at Month 12

Femoral neck BMD was assessed by DXA scans evaluated by a central imaging laboratory. Positive changes from baseline indicate improvement in bone health.

ITT Population: All participants randomized into the study. Here, overall number of participants analyzed = participants evaluable for this outcome measure.

Posted

Least Squares Mean

Standard Error

percent change

Baseline, Month 12

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000

Secondary

Percent Change From Baseline in Lumbar Spine BMD at Month 6

Lumbar Spine BMD was assessed by DXA scans evaluated by a central imaging laboratory. Lumbar spine scans included L1 through L4. Positive changes from baseline indicate improvement in bone health.

ITT Population: All participants randomized into the study. Here, overall number of participants analyzed = participants evaluable for this outcome measure.

Posted

Least Squares Mean

Standard Error

percent change

Baseline, Month 6

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000

Secondary

Percent Change in Total Hip BMD From Baseline at Month 6

Total hip BMD was assessed by DXA scans evaluated by a central imaging laboratory. Positive changes from baseline indicate improvement in bone health.

ITT Population: All participants randomized into the study. Here, overall number of participants analyzed = participants evaluable for this outcome measure.

Posted

Least Squares Mean

Standard Error

percent change

Baseline, Month 6

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000

Secondary

Percent Change From Baseline in Femoral Neck BMD at Month 6

Femoral neck BMD was assessed by DXA scans evaluated by a central imaging laboratory. Positive changes from baseline indicate improvement in bone health.

ITT Population: All participants randomized into the study. Here, overall number of participants analyzed = participants evaluable for this outcome measure.

Posted

Least Squares Mean

Standard Error

percent change

Baseline, Month 6

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000

Secondary

Percent Change From Baseline in Ultra-Distal Radius BMD at Month 12

Ultra-distal radius BMD was assessed by DXA scans. Positive changes from baseline indicate improvement in bone health.

ITT Population: All participants randomized into the study. Here, overall number of participants analyzed = participants evaluable for this outcome measure.

Posted

Least Squares Mean

Standard Error

percent change

Baseline, Month 12

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000

Secondary

Percent Change From Baseline in Distal One-third Radius BMD at Month 12

Distal one-third radius BMD was assessed by DXA scans. Positive changes from baseline indicate improvement in bone health.

ITT Population: All participants randomized into the study. Here, overall number of participants analyzed = participants evaluable for this outcome measure.

Posted

Least Squares Mean

Standard Error

percent change

Baseline, Month 12

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000

Secondary

Percent Change From Baseline in Serum Procollagen Type I N-terminal Propeptide (s-PINP) at Month 12

Blood samples were taken to measure s-PINP, a bone formation marker. s-PINP concentrations reflect the rate of skeletal new bone formation. Increases in s-PINP indicate anabolic biologic response in the bone.

ITT Population: All participants randomized into the study. Here, overall number of participants analyzed is the total number of participants who had s-PINP evaluation at Baseline and Month 12.

Posted

Mean

Standard Deviation

percent change

Baseline, Month 12

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000

Secondary

Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) at Month 12

Blood samples were taken to measure s-CTX. Elevated levels of s-CTX indicate increased bone resorption (bone loss).

ITT Population: All participants randomized into the study. Here, overall number of participants analyzed is the total number of participants who had s-CTX evaluation at Baseline and Month 12.

Posted

Mean

Standard Deviation

percent change

Baseline, Month 12

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000

Secondary

Number of Participants With New Clinical Fractures

Radiological evaluations were performed to identify any new clinical fractures (occurring after the screening visit).

ITT Population: All participants randomized into the study.

Posted

Count of Participants

Participants

Baseline through Month 12

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000

Secondary

Percent of Participants With Change in Disease Status

The percentage of participants converting from the categories of osteoporosis to osteopenia or from osteopenia to normal at End of Treatment (Month 12) was assessed. Osteoporosis was defined as lumbar spine or total hip BMD T-score ≤ -2.5. Osteopenia was defined as one of the following:

Lumbar spine > -2.5 and total hip BMD T-score > -2.5 and < -1.0
Lumbar spine > -2.5 and < -1.0 and total hip BMD T-score > -2.5
Normal was defined as lumbar spine and total hip BMD T-score ≥ -1.0.

ITT Population: All participants randomized into the study. Here, overall number of participants analyzed is the total number of participants who had baseline evaluation and also had end of treatment BMD disease category evaluation (normal, osteopenia, and osteoporosis).

Posted

Number

percentage of participants

Baseline through Month 12

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Secondary

Percent of Participants Experiencing BMD Gains From Baseline of > 0%, > 3%, and > 6% at the Lumbar Spine, Femoral Neck, and Total Hip

Lumbar spine, femoral neck, and total hip BMD were assessed by DXA scans evaluated by a central imaging laboratory.

ITT Population: All participants randomized into the study. Here, overall number of participants analyzed = participants evaluable for this outcome measure.

Posted

Number

percentage of participants

Month 12

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000

Secondary

Percent Change From Baseline in Total Hip Volumetric BMD as Measured by Quantitative Computed Tomography (QCT) at Month 12

QCT scans were evaluated by a central imaging laboratory.

Only 2 participants per reporting group had volumetric BMD measured by QCT at baseline and Month 12, therefore, no data is reported here to maintain participant confidentiality.

Posted

Baseline, Month 12

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000

Secondary

Percent Change From Baseline in Femoral Neck Volumetric BMD as Measured by QCT at Month 12

QCT scans were evaluated by a central imaging laboratory.

Only 2 participants per reporting group had volumetric BMD measured by QCT at baseline and Month 12, therefore, no data is reported here to maintain participant confidentiality.

Posted

Baseline, Month 12

ID	Title	Description
OG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.
OG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.

Units	Counts
Participants	OG000

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Abaloparatide	Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.	1	149	8	149	73	149
EG001	Placebo	Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen.	0	79	4	79	29	79

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Angina unstable	Cardiac disorders	MedDRA 24.0	Systematic Assessment	EG0001 affected149 at risk EG0010 affected79 at risk
Supraventricular tachycardia	Cardiac disorders	MedDRA 24.0	Systematic Assessment	EG0001 affected149 at risk EG0010 affected79 at risk
Acute myocardial infarction	Cardiac disorders	MedDRA 24.0	Systematic Assessment	EG0000 affected149 at risk EG0011 affected79 at risk
Mitral valve prolapse	Cardiac disorders	MedDRA 24.0	Systematic Assessment	EG0000 affected149 at risk EG0011 affected79 at risk
Small intestinal obstruction	Gastrointestinal disorders	MedDRA 24.0	Systematic Assessment	EG0001 affected149 at risk EG0010 affected79 at risk
Skin graft rejection	Immune system disorders	MedDRA 24.0	Systematic Assessment	EG0000 affected149 at risk EG0011 affected79 at risk
Appendicitis	Infections and infestations	MedDRA 24.0	Systematic Assessment	EG0001 affected149 at risk EG0010 affected79 at risk
Influenza	Infections and infestations	MedDRA 24.0	Systematic Assessment	EG0001 affected149 at risk EG0010 affected79 at risk
Burns third degree	Injury, poisoning and procedural complications	MedDRA 24.0	Systematic Assessment	EG0000 affected149 at risk EG0011 affected79 at risk
Lumbar spinal stenosis	Musculoskeletal and connective tissue disorders	MedDRA 24.0	Systematic Assessment	EG0000 affected149 at risk EG0011 affected79 at risk
Lung adenocarcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 24.0	Systematic Assessment	EG0001 affected149 at risk EG0010 affected79 at risk
Cerebrovascular accident	Nervous system disorders	MedDRA 24.0	Systematic Assessment	EG0001 affected149 at risk EG0010 affected79 at risk
Peripheral nerve palsy	Nervous system disorders	MedDRA 24.0	Systematic Assessment	EG0001 affected149 at risk EG0010 affected79 at risk
Toxicity to various agents	Injury, poisoning and procedural complications	MedDRA 24.0	Systematic Assessment	EG0001 affected149 at risk EG0010 affected79 at risk
Chronic obstructive pulmonary disease	Respiratory, thoracic and mediastinal disorders	MedDRA 24.0	Systematic Assessment	EG0001 affected149 at risk EG0010 affected79 at risk

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Injection site erythema	General disorders	MedDRA 24.0	Systematic Assessment	EG00019 affected149 at risk EG0014 affected79 at risk
Injection site swelling	General disorders	MedDRA 24.0	Systematic Assessment	EG00010 affected149 at risk EG0010 affected79 at risk
Injection site pain	General disorders	MedDRA 24.0	Systematic Assessment	EG0009 affected149 at risk EG0010 affected79 at risk
Nasopharyngitis	Infections and infestations	MedDRA 24.0	Systematic Assessment	EG00013 affected149 at risk EG0016 affected79 at risk
Bronchitis	Infections and infestations	MedDRA 24.0	Systematic Assessment	EG0008 affected149 at risk EG0011 affected79 at risk
Upper respiratory tract infection	Infections and infestations	MedDRA 24.0	Systematic Assessment	EG0007 affected149 at risk EG0015 affected79 at risk
Sinusitis	Infections and infestations	MedDRA 24.0	Systematic Assessment	EG0006 affected149 at risk EG0014 affected79 at risk
Arthralgia	Musculoskeletal and connective tissue disorders	MedDRA 24.0	Systematic Assessment	EG00010 affected149 at risk EG0011 affected79 at risk
Back pain	Musculoskeletal and connective tissue disorders	MedDRA 24.0	Systematic Assessment	EG0007 affected149 at risk EG0015 affected79 at risk
Dizziness	Nervous system disorders	MedDRA 24.0	Systematic Assessment	EG00013 affected149 at risk EG0011 affected79 at risk
Headache	Nervous system disorders	MedDRA 24.0	Systematic Assessment	EG0008 affected149 at risk EG0014 affected79 at risk
Hypertension	Vascular disorders	MedDRA 24.0	Systematic Assessment	EG0008 affected149 at risk EG0014 affected79 at risk

First MCP Posted Date

ID	Term
D010024	Osteoporosis
D050723	Fractures, Bone
D001851	Bone Diseases, Metabolic

ID	Term
C000596789	abaloparatide

ID	Term
D001847	Bone Diseases
D009140	Musculoskeletal Diseases
D008659	Metabolic Diseases
D009750	Nutritional and Metabolic Diseases
D014947	Wounds and Injuries